Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims

Delist
Court rules Jazz's Xyrem patent should be delisted from FDA's Orange Book • Source: Shutterstock

More from Legal & IP

More from Pink Sheet